Back to Search Start Over

Biomarkers and Lung Cancer Early Detection: State of the Art

Authors :
Fabrizio Bianchi
Marco Cremonesi
Tommaso Colangelo
Emanuela Fina
Giulia Veronesi
Marinos Kallikourdis
Elisa Dama
Dama, E.
Colangelo, T.
Fina, E.
Cremonesi, M.
Kallikourdis, M.
Veronesi, G.
Bianchi, F.
Source :
Cancers, Vol 13, Iss 3919, p 3919 (2021), Cancers
Publication Year :
2021
Publisher :
MDPI AG, 2021.

Abstract

Simple Summary Lung cancer is the leading cause of cancer death worldwide. Detecting lung malignancies promptly is essential for any anticancer treatment to reduce mortality and morbidity, especially in high-risk individuals. The use of liquid biopsy to detect circulating biomarkers such as RNA, microRNA, DNA, proteins, autoantibodies in the blood, as well as circulating tumor cells (CTCs), can substantially change the way we manage lung cancer patients by improving disease stratification using intrinsic molecular characteristics, identification of therapeutic targets and monitoring molecular residual disease. Here, we made an update on recent developments in liquid biopsy-based biomarkers for lung cancer early diagnosis, and we propose guidelines for an accurate study design, execution, and data interpretation for biomarker development. Abstract Lung cancer burden is increasing, with 2 million deaths/year worldwide. Current limitations in early detection impede lung cancer diagnosis when the disease is still localized and thus more curable by surgery or multimodality treatment. Liquid biopsy is emerging as an important tool for lung cancer early detection and for monitoring therapy response. Here, we reviewed recent advances in liquid biopsy for early diagnosis of lung cancer. We summarized DNA- or RNA-based biomarkers, proteins, autoantibodies circulating in the blood, as well as circulating tumor cells (CTCs), and compared the most promising studies in terms of biomarkers prediction performance. While we observed an overall good performance for the proposed biomarkers, we noticed some critical aspects which may complicate the successful translation of these biomarkers into the clinical setting. We, therefore, proposed a roadmap for successful development of lung cancer biomarkers during the discovery, prioritization, and clinical validation phase. The integration of innovative minimally invasive biomarkers in screening programs is highly demanded to augment lung cancer early detection.

Details

Language :
English
ISSN :
20726694
Volume :
13
Issue :
3919
Database :
OpenAIRE
Journal :
Cancers
Accession number :
edsair.doi.dedup.....6d579ea1fb73220698a861530fde9912